Saris­sa's Alk­er­mes board re­place­ments large­ly fail to win sup­port from share­hold­er firms, which cite Bio­gen board moves

Alex Den­ner, the in­vestor be­hind the ac­tivist firm Saris­sa Cap­i­tal Man­age­ment, is not win­ning much sup­port for his board up­heaval plans at Irish drug­mak­er Alk­er­mes.

On Tues­day and Wednes­day this week, Alk­er­mes said that share­hold­er ad­vi­so­ry firm ISS and proxy ad­vi­so­ry shop Glass Lewis rec­om­mend­ed that share­hold­ers not sup­port Den­ner’s ap­point­ment to the board, nor Saris­sa pres­i­dent Patrice Bon­figlio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER